Drug General Information (ID: DDIF8GZODP)
Drug Name			Eluxadoline		Drug Info		Methscopolamine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Peripheral Opioid Receptor Mixed Agonists/Antagonists				Anticholinergic Agents
Structure

Mechanism of Eluxadoline-Methscopolamine Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Eluxadoline				Methscopolamine
Mechanism		Constipation				Constipation
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Eluxadoline and Methscopolamine

Recommended Action
Management		Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.